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T cells and Tregs was higher in HPV-positive than HPV-
negative OPSCC (p < 0.0001). In contrast, HPV-negative 
OPSCC contained significantly higher numbers of IL-17+ 
non-T cells (p < 0.0001). Although a high number of intra-
tumoral T cells showed a trend toward improved survival 
of all OPSCC patients, their prognostic effect in patients 
with a low number of intra-tumoral IL-17+ non-T cells 
was significant with regard to disease-specific (p = 0.033) 
and disease-free survival (p = 0.012). This suggests that 
a high frequency of IL-17+ non-T cells was related to a 
poor immune response, which was further supported by 
the observation that a high number of T cells was cor-
related with improved disease-free survival in the HPV-
positive OPSCC (p = 0.008). In addition, we detected a 
minor Th17 cell population. However, T cells obtained 
from HPV-positive OPSCC produced significantly more 
IL-17 than those from HPV-negative tumors (p = 0.006). 
The improved prognosis of HPV-positive OPSCC is thus 
correlated with higher numbers of tumor-infiltrating T 
cells, more active Th17 cells and lower numbers of IL-17+ 
non-T cells.
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Abstract  Patients with HPV-positive oropharyngeal 
squamous cell carcinomas (OPSCCs) have a better prog-
nosis than patients with non-HPV-induced OPSCC. The 
role of the immune response in this phenomenon is yet 
unclear. We studied the number of T cells, regulatory T 
cells (Tregs), T helper 17 (Th17) cells and IL-17+ non-T 
cells (mainly granulocytes) in matched HPV-positive and 
HPV-negative OPSCC cases (n = 162). Furthermore, 
the production of IFN-γ and IL-17 by tumor-infiltrating 
T cells was analyzed. The number of tumor-infiltrating 
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Introduction
Oropharyngeal squamous cell carcinoma (OPSCC) can be 
divided into subtypes with different etiologies, one subtype 
due to alcohol and tobacco use and another due to persistent 
infection with high-risk human papillomavirus (HPV) [1, 
2]. The incidence of OPSCC and the prevalence of HPV-
associated tumors are increasing in Europe and the USA 
[3–7]. The reported proportion of HPV-positive OPSCC 
ranges from 20 to 90 %. This high variation between stud-
ies may be related to the time period in which HPV preva-
lence was investigated as well as to the lack of a standard-
ized HPV detection assay [8]. Remarkably, patients with 
HPV-positive OPSCC have a significantly better prognosis 
than patients with non-HPV-induced tumors [8–11]. How-
ever, heavy smoking habits seem to undo the beneficial 
effect of HPV positivity on survival [12].
A different type of cancer, arising in the cervix uteri, 
is practically always initiated by a persistent HPV infec-
tion [13]. From studies on cervical HPV infections, HPV 
is known to be cleared in over 90 % of cases [14]. In case 
of cervical cancer development, the tumor cells are thought 
to manipulate the immune response such that it facilitates 
tumor growth [15]. In addition, the immune response pre-
sent in the tumor microenvironment is critical for clini-
cal outcome. As OPSCC can be divided in virally induced 
and non-virally induced subtypes, this tumor type provides 
a means to study the relationship between the immune 
response and clinical outcome as a function of viral etiol-
ogy. A high frequency of intratumoral CD8+ cytotoxic T 
cells has been found to be correlated with improved survival 
in OPSCC [16]. However, data are still limited for other T 
cell subsets in OPSCC, including regulatory T cells (Tregs).
The role of Tregs in cancer in general seems to be con-
text and tumor type dependent [17], with correlations 
reported between a high Treg frequency and poor prognosis 
[18–20] but also improved prognosis [21–24]. The role of 
T helper 17 (Th17) cells and other IL-17 expressing cells 
is unclear, with contradictory functions attributed to this 
cell type in cancer [25]. We have recently shown that Th17 
cells tend to be correlated with improved survival, while 
total IL-17, predominantly expressed by granulocytes, cor-
related with poor survival in cancer patients [26, 27].
The aim of this study was to elucidate the role of the 
immune response in virally induced versus non-virally induced 
OPSCC. We determined the distribution of intra-epithelial 
and stromal T cells, Tregs, Th17 and IL-17+ non-T cells with 
regard to HPV status in a large series of OPSCC cases and ana-
lyzed the correlations with patient survival. The IL-17+ non-T 
cells were included in these analyses, because we previously 
found that on average only 6 % of the tumor-infiltrating IL-17+ 
cells in head and neck cancer were Th17 cells, while 45 % 
were granulocytes [26]. In addition, the production of IFN-γ 
and IL-17 by tumor-infiltrating lymphocytes upon mitogenic 
stimulation was compared in HPV-positive and HPV-negative 
tumors. Because of the differences in survival based on HPV 
status, the differences in immune response between OPSCC 
groups may indicate markers of a beneficial immune response. 
We hypothesized that HPV-positive tumors are characterized 
by a different quantity and composition of immune cell infil-
trates. We expect that total T cells and Th17 cells are correlated 
with improved clinical outcome, while Tregs and IL-17+ non-
Th17 cells are correlated with poor outcome for patients.
Materials and methods
Patient material
For this study, we searched the hospital-based cancer regis-
try Oncology Documentation (ONCDOC) of the LUMC for 
all primary oropharyngeal tumors, diagnosed between 1970 
and 2011. Trained data managers scored all patient, treat-
ment and follow-up data. These data were retrieved from 
the patients’ medical record and hospital-based data system. 
ONCDOC also performs an independent and active follow-
up. Formaldehyde fixed, paraffin-embedded (FFPE) pre-
treatment tumor samples from 341 patients were obtained 
from the archives of the Pathology Department of the 
LUMC. A dedicated pathologist (Senada Koljenović) ana-
lyzed the tumor samples for the presence of malignant cells. 
Thirty tumor samples (8.8 %) were excluded for further 
analysis due to the absence of malignant cells. All included 
patients were treated following standard guidelines that 
applied in the year of diagnosis. Patient and tumor charac-
teristics are listed in Table 1. The median follow-up time of 
the 162 patients selected for final analysis was 37 months. 
Patient samples were handled according to the medical ethi-
cal guidelines described in the Code of Conduct for Proper 
Secondary Use of Human Tissue of the Dutch Federation of 
Biomedical Scientific Societies (www.federa.org).
p16 and HPV detection
FFPE tumor specimens from 311 patients were cut into 
4-µm-thick sections, deparaffinized and stained for p16 
(INK4A; Roche MTM Laboratories AG, Heidelberg, Ger-
many) using a fully automated Ventana BenchMark ULTRA 
Stainer (Ventana, Tucson Arizona, USA) according to the 
manufacturers’ instructions. Binding of peroxidase-coupled 
antibodies was visualized using 3,3′-diamino-benzidine-
tetrahydrochloride (DAB). Slides were counterstained with 
hematoxylin. P16 immunostained samples were scored inde-
pendently by two dedicated pathologists (Senada Koljenović, 
Elisabeth Bloemena). The tumor samples were scored as ‘p16 
positive’ when >70 % of the tumor cells showed both nuclear 
and cytoplasmic staining.
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High-risk HPV DNA detection was performed on the 
p16-positive cases. DNA was extracted from all p16 posi-
tive cases using an automated silica-based extraction sys-
tem, and PCR was performed using the HPV-Risk assay 
(Self-Screen BV, Amsterdam, the Netherlands) [28]. The 
HPV-Risk assay is a novel real-time PCR assay targeting 
the E7 region of 15 high-risk HPV types (i.e., HPV 16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 67 and 68) 
Table 1  Patient and tumor characteristics
1 Clinical TNM classification of the tumor size (T) and the involvement of regional lymph nodes (N) and distant metastases (M)
Clinicopathological parameter Category HPV-negative tumors (%) (n = 99) HPV-positive tumors (%) (n = 63)
Age Median (years) 60 57
Range (years) 41–86 43–90
Sex Female 32 (32) 25 (40)
Male 67 (68) 38 (60)
Tumor location Base of tongue 23 (23) 16 (25)
Tonsil 25 (25) 31 (49)
Tonsillar fossa 26 (26) 9 (14)
Oropharyngeal wall 13 (13) 4 (6)
Soft palate 8 (8) 1 (2)
Vallecula 1 (1) 2 (3)
Uvula 3 (3) 0 (0)
Tumor morphology Squamous cell (unspecified) 35 (35) 32 (51)
Keratinizing squamous cell 45 (45) 14 (22)
Non-keratinizing squamous large cell 16 (16) 16 (25)
Papillary squamous cell 2 (2) 1 (2)
Squamous spindle cell 1 (1) 0 (0)
TNM stage1 T1 16 (16) 19 (30)
T2 33 (33) 27 (43)
T3 26 (26) 13 (21)
T4 24 (24) 4 (6)
N0 38 (38) 9 (14)
N1 22 (22) 13 (21)
N2 33 (33) 38 (60)
N3 6 (6) 3 (5)
M0 97 (98) 62 (98)
M1 2 (2) 1 (2)
Local recurrence No 83 (84) 55 (87)
Yes 16 (16) 8 (13)
Regional recurrence No 82 (83) 57 (90)
Yes 17 (17) 6 (10)
Distant metastasis No 84 (85) 57 (90)
Yes 15 (15) 6 (10)
Deceased No 29 (29) 45 (71)
Yes 70 (71) 18 (29)
Follow-up time Median (months) 28 55
Prior tumor No 93 (94) 55 (87)
Yes 6 (6) 8 (13)
Smoking Never 9 (9) 19 (30)
Medium (1–24 PY) 8 (8) 11 (18)
Heavy (>24 PY) 33 (33) 15 (24)
Unknown 49 (50) 18 (28)
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and provides additional genotype information for HPV 
16 and HPV 18. The HPV-Risk assay is clinically vali-
dated and meets the cross-sectional clinical and reproduc-
ibility criteria of the international guidelines for HPV test 
requirements.
Matching
All p16 positive cases (n = 94) were included in this 
study as well as n = 94 p16 negative cases that were 
matched for tumor T stage, N stage, location, patient 
gender and decennium of diagnosis. Hence, a subset of 
n = 188 out of n = 311 patients was selected for the pre-
sent study.
Immunofluorescent stainings
Part of the selected n = 188 tumor samples could not be 
analyzed due to insufficient tumor material to obtain at 
least one microscopic image (n = 26). Triple immuno-
fluorescent staining for CD3 (ab828, Abcam, Cambride, 
UK), FoxP3 (ab20034, Abcam) and IL-17 (AF-317-NA, 
R&D Systems, Abingdon, UK) was performed on 162 
tumor samples as described before [29]. These comprised 
86 p16 positive and 76 p16 negative tumors. Images 
were obtained using an LSM700 confocal laser scanning 
microscope containing an LCI Plan-Neofluar 25×/0.8 
Imm Korr DIC M27 objective (Zeiss, Göttingen, Ger-
many). One to four random images sampled a total vital 
tumor (epithelium + stroma) area of up to 1.0 mm2. Total 
tumor epithelium and stroma surface area and double or 
triple positivity of cells were determined in each image 
using LSM Image Browser (version 4.2.0.121, Zeiss). 
Single-, double- and triple-positive cells were scored 
separately in the tumor epithelial and stromal areas using 
ImageJ version 1.47 (http://rsb.info.nih.gov/ij). Cells 
within blood vessels and largely autofluorescent areas 
were not scored.
TIL isolation and cytokine analysis
Fresh OPSCC tissue was cut into small pieces of ~1 mm3 
and cultured in IMDM (Lonza), supplemented with 10 % 
human AB serum (Life Technology) and two–three times 
a week 1000 IU/mL IL-2 (Novartis Aldesleukin). TIL were 
cultured for two–four weeks to obtain sufficient cells for 
testing their response to PHA stimulation (in triplicate 
wells). Unstimulated T cells were used as a negative con-
trol. Supernatant (50 µl/well) was harvested after 4 days 
of stimulation and used for cytokine analysis. The pro-
duction of IFN-γ (Sanquin) and IL-17A (eBiosciences) 
was analyzed according to the manufacturers’ ELISA kit 
guidelines.
Statistical analysis
Statistical analyses were performed using SPSS version 
20.0 (IBM Corp., Armonk, USA) and R version 3.1.1. 
(packages: foreign, mice, rms, survival). Differences in 
the numbers of positive cells between patient groups were 
tested using the Wilcoxon Mann–Whitney tests. Correla-
tions (r) between cell frequencies were tested using the 
Spearman’s rank correlation rho test. For each disease-free 
(time from diagnosis until local or distant recurrence or 
death to disease) and disease-specific (time from diagnosis 
until death to disease) survival, Kaplan–Meier curve gener-
ation and log rank analysis, the cell numbers were divided 
into four equal quartiles and the lowest quartile (low fre-
quency) was compared with the other quartiles (high fre-
quency). For comparisons based on a ratio or other combi-
nation of cell frequencies, patients were divided into a high 
and low group based on the median. Missing values for 
the variable ‘smoking status’ were handled by performing 
multiple imputation using the package ‘mice’ in R. All vari-
ables included in Table 1 were used for imputation. N = 5 
imputations were performed, and the pooled imputed data 
were used in multivariate analyses. Multivariate analysis 
was performed using Cox proportional hazard regression 
analysis. All tests were two-sided, and p values below 0.05 
were considered statistically significant.
Results
HPV analysis
Of the initial 311 tumor samples that were evaluated 
for HPV status, 94 (30 %) were scored ‘p16 positive.’ 
The inter-observer variability between the scoring of all 
tumor samples by two pathologists was 0.867 (kappa sta-
tistic, p < 0.001). Of the p16 positive cases, 70 (74.4 %) 
contained high-risk HPV DNA, of which 63 (90 %) were 
HPV 16 positive, and 7 (10 %) contained HPV 18 or other 
types of high-risk HPV. The variability between the p16 
and PCR analyses was 0.774 (kappa statistic, p < 0.001). 
After matching all p16 positive cases (n = 94) for tumor T 
stage, N stage, location, patient gender and decennium of 
diagnosis with an equal amount of p16 negative cases, only 
162 samples were suitable for further analysis by immuno-
fluorescence. Of this subset of tumor samples, 86 were p16 
positive and 76 were p16 negative. A proportion of 73.3 % 
(n = 63) of the p16 positive cases contained high-risk 
HPV DNA. Only these 63 cases were taken into account as 
HPV positive in further analysis. As a result, p16 positive 
but HPV DNA negative cases were considered HPV nega-
tive (n = 21). N stage, location of tumor, patient gender, 
patient age and level of comorbidity were not significantly 
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different between the HPV-positive and HPV-negative 
cases. A higher T stage was observed in the HPV-negative 
patients, which might be due to the p16 positive HPV-neg-
ative patients to be considered HPV negative in the final 
analysis. However, adding T stage to the multivariate anal-
yses did not influence the significance of the results.
HPV‑positive tumors are more heavily infiltrated by T 
cells and less by IL‑17+ non‑T cells
Irrespective of HPV status, all tumor samples were infil-
trated by CD3+ T cells, which comprised a substantial 
population of CD3+FoxP3+ Tregs (Fig. 1, Supplementary 
Fig. 1 and Supplementary Table 1). IL-17+ cells represented 
another substantial infiltrating immune cell population, 
whereas only a minor population of CD3+IL-17+ Th17 cells 
was observed. FoxP3+ cells were always positive for CD3. 
FoxP3+IL-17+ cells were observed very infrequently—at 
maximum five cells in all samples comprising 0.01 % of 
FoxP3+ cells—and were thus not further analyzed.
HPV-positive tumors contained significantly higher num-
bers of CD3+ T cells infiltrating in the tumor epithelium 
(p < 0.0001) and the tumor stroma (p < 0.0001). Because 
the increase in T cells in HPV-positive tumors was similar 
in the epithelium, stroma and the combined tumor epithe-
lium and stroma field, the significantly increased numbers 
of CD3+ T cells in the HPV-positive compared to the HPV-
negative tumors are shown in Fig. 2a for the combined area 
(p < 0.0001). The number of CD3+FoxP3+ Tregs infil-
trating in the tumor epithelium (p < 0.0001) and stroma 
(p < 0.0001) was also significantly higher in HPV-positive 
tumors. The increased number of Tregs in the tumor epi-
thelium and stroma combined in HPV-positive tumors is 
shown in Fig. 2b (p < 0.0001). However, the average ratio 
of total T cells over Tregs was twice as high in HPV-positive 
tumors compared to HPV-negative tumors (Supplementary 
Table 1). Non-Treg T cells were thus particularly increased 
in HPV-positive tumors. In contrast, the number of IL-17+ 
non-T cells was significantly higher in the tumor epithelium 
(p = 0.003), the stroma (p = 0.004) and the tumor epithe-
lium and stroma combined (p < 0.0001, Fig. 2c) of HPV-
negative compared to HPV-positive tumors. The frequency 
of Th17 cells was not significantly different between HPV-
positive and HPV-negative tumors (Fig. 2d).
The frequency of infiltrating Tregs was significantly 
correlated with the frequency of total infiltrating T cells in 
Fig. 1  Representative image of an oropharyngeal cancer specimen 
stained by triple immunofluorescence for CD3 (a, red), IL-17 (b, 
green) and FoxP3 (c, blue), with the combined stainings together with 
DAPI counterstain (gray) shown in d. The arrows indicate two Th17 
cells double positive for IL-17 and CD3
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both HPV-positive (r = 0.676, p < 0.0001) and HPV-nega-
tive tumors (r = 0.877, p < 0.0001). The frequency of infil-
trating IL-17+ cells was not significantly correlated with 
the frequency of total infiltrating T cells (data not shown).
Infiltrating T cells are correlated with improved 
survival in combination with low IL‑17+ non‑T cell 
frequencies
We subsequently studied the correlations between the infil-
trating immune cell frequencies and patient survival. Since 
the correlations for stromal and total cell numbers were 
similar, the correlations for intra-epithelial and total cell 
numbers are discussed. A high number of infiltrating total 
T cells in all patients combined showed a trend toward cor-
relation with improved disease-specific (p = 0.089, data 
not shown) and disease-free survival (0.086, Fig. 3a) com-
pared to a low number of T cells (i.e., lowest quartile). Pre-
viously, we found that cervical cancer-infiltrating IL-17+ 
cells, representing mainly granulocytes, were associated 
with poor survival [26]. We, therefore, divided the patients 
based on the median number of IL-17+ cells. Among 
patients with a low number of IL-17+ cells, a high num-
ber of total infiltrating T cells was correlated with improved 
disease-specific (p = 0.033, data not shown) and disease-
free survival (p = 0.012, Fig. 3b) when compared to a low 
T cell frequency. The prognostic effect of tumor-infiltrat-
ing T cells was lost in the group of patients with an above 
number of tumor-infiltrating IL-17+ cells (data not shown). 
Thus, the effect of tumor-infiltrating T cells in OPSCC may 
be related to the low number of IL-17+ cells present.
We further studied the survival correlations among 
patients with HPV-positive tumors. The presence of HPV in 
OPSCC tumors was significantly correlated with improved 
disease-specific (p = 0.0001) and disease-free survival 
(p < 0.0001, data not shown), corresponding to earlier stud-
ies [30, 31]. Since p16-positive tumors were matched to 
p16-negative tumors for factors that may contribute to prog-
nosis, these factors were equally distributed over the groups 
of HPV-positive and HPV-negative tumors and similarly 
Fig. 2  Tumor-infiltrating T cells and IL-17+ cells in HPV-posi-
tive and HPV-negative tumors. The number of CD3+ T cells (a), 
FoxP3+CD3+ Tregs (b), CD3-IL-17+ cells (c) and CD3+IL-17+ 
Th17 cells (d) infiltrating in the combined tumor epithelium and 
stroma per mm2 is shown for HPV-negative tumors and HPV-positive 
tumors. The bars indicate the mean and 95 % confidence interval; n.s. 
not significant
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correlated with survival. When corrected for comorbidity, 
prior tumor occurrence and smoking status, the hazard ratio 
for a recurrence or death to disease with an HPV-positive 
compared to an HPV-negative tumor was 0.334 (95 % 
CI: 0.185-0.605, p < 0.0001). Analysis of the correla-
tion between tumor-infiltrating immune cells and survival 
revealed that among patients with HPV-positive tumors, 
which displayed significantly lower numbers of IL17+ cells 
than the HPV-negative tumors, a high number of intra-epi-
thelial T cells was indeed correlated with improved disease-
free survival (p = 0.003, Fig. 4a) compared to a low intra-
epithelial T cell frequency (i.e., lowest quartile). Similarly, 
a high non-Treg intra-epithelial T cell frequency showed 
a trend toward a correlation with improved disease-free 
survival (p = 0.064, Fig. 4b). Furthermore, a high T cell 
frequency, a high CD3+FoxP3− non-Treg T cell frequency 
and a high Treg frequency infiltrating the total tumor area 
(epithelium and stroma combined) of HPV-positive tumors 
were all significantly correlated with improved disease-free 
survival (p = 0.008, p = 0.008, p = 0.003, respectively; 
Fig. 4c–e). We also found a trend toward a positive correla-
tion between a high Treg frequency in the total tumor area 
and disease-specific survival (p = 0.055, data not shown). 
We did not find significant correlations between the IL-17+ 
cell frequencies and disease-free or disease-specific sur-
vival among patients with HPV-positive tumors, probably 
because in most cases the numbers were low when com-
pared to HPV-negative tumors. Only a high intra-epithelial 
T cell frequency remained significantly correlated with 
disease-free survival when corrected for comorbidity, prior 
tumor occurrence and smoking status in a multivariate 
analysis (Supplementary Table 2).
For patients with HPV-negative tumors, we only found 
a significant correlation for a high T cell/IL-17+ non-T cell 
ratio and improved disease-specific survival (p = 0.043, 
data not shown). No significant direct correlations between 
the T cell, Treg or IL-17+ cell frequencies and disease-free 
or disease-specific survival were found (Supplementary 
Table 2), while the effect of other factors that may contrib-
ute to prognosis (comorbidity, prior tumor occurrence and 
smoking status) remained similar to the effect in patients 
with HPV-positive tumors (data not shown).
Epithelium infiltrating T cells in HPV‑positive tumors 
are inversely correlated with smoking status
Because of the correlation described between smoking 
habits and prognosis in HPV-positive tumors [12], we won-
dered whether smoking habits may directly influence the 
tumor infiltration of T cells. Indeed, HPV-positive tumors 
of heavy smokers (>24 pack-years) were significantly 
correlated with a lower intra-epithelial T cell frequency 
compared to tumors of never smokers (p = 0.003, Supple-
mentary Fig. 2). The other cell type studies were not sig-
nificantly correlated with smoking status (data not shown).
HPV‑positive tumor‑infiltrating T cells produce IL‑17 
upon activation
To study whether the production of effector molecules was 
influenced by the presence of HPV, we isolated the tumor-
infiltrating T cells from 11 HPV-negative OPSCC and 11 
HPV-positive OPSCC and assessed cytokine production 
after 4 days of stimulation with PHA. We studied IFN-γ 
production as a measure for effector non-Treg T cells, and 
IL-17 production as a measure for Th17 cells. While IFN-γ 
was produced in all cases, the TILs isolated from HPV-pos-
itive tumors produced IL-17 more frequently (p = 0.006) 
(Fig. 5a, b), suggesting that functional Th17 cells are espe-
cially present in HPV-positive tumors.
Fig. 3  Kaplan–Meier disease-free survival curves for a low (i.e., 
lowest quartile) versus higher number of total T cells among all 
patients (a) and a low (i.e., below median) versus high number 
of total T cells among the patients with a below median number of 
IL-17+ cells/mm2 (b) in the tumor epithelium and stroma combined
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Discussion
HPV-positive OPSCC contained more tumor-infiltrating T 
cells and less IL-17+ non-T cells compared to HPV-neg-
ative tumors in both the epithelial and stromal part of the 
tumor. An increased number of CD3+, CD8+ and Treg cells 
[32–34] and a trend toward a decreased number of IL-17+ 
cells [35] infiltrating HPV-positive compared to HPV-neg-
ative OPSCC have been shown previously [36]. Although 
correlations between a high tumor-infiltrating lymphocyte 
frequency and improved survival in both patients with 
HPV-positive [37] and HPV-negative tumors [16, 33, 38] 
have been described before, data regarding the T cell sub-
types involved have been limited and inconclusive. The 
current study revealed that a high number of intra-tumoral 
T cells showed a trend toward better survival of all (HPV-
positive and HPV-negative) OPSCC patients. Since we 
have shown before that a high frequency of IL-17+ non-T 
cells, representing mainly granulocytes is correlated with 
poor survival in early-stage squamous cervical cancer [26], 
Fig. 4  Among patients with HPV-positive tumors (n = 63), Kaplan–
Meier curves are shown for a low versus high number of total T cells 
(a) and non-Treg T cells (b) within the tumor epithelium (IE) and a 
low versus high T cell (c), non-Treg T cell (d) and Treg (e) frequency 
in the total tumor area (epithelium and stroma combined)
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here we studied the effect of tumor-infiltrating T cells strat-
ified for a high or low number of infiltrating IL-17+ cells. 
In patients with a below median number of intra-tumoral 
IL-17+ non-T cells, a high tumor-infiltrating T cell fre-
quency was correlated with improved disease-free and 
disease-specific survival, suggesting that a high frequency 
of IL-17+ cells is related to a poor immune response. No 
significant correlation was observed in tumors with a high 
number of IL-17+ non-T cells. The hypothesis was further 
substantiated by the observation that in the HPV-positive 
OPSCC, which contained less IL-17+ cells than HPV-neg-
ative OPSCC, a high number of T cells was correlated with 
improved disease-free survival. This suggests that IL-17+ 
non-T cells may be correlated with an unfavorable immune 
response. Such a tumor-promoting role can be explained 
by the role of IL-17 in driving inflammation, angiogenesis 
and tumor growth, and studies so far have indeed described 
correlations between IL-17 and poor survival in cancer 
patients [27]. Thus, the beneficial effect of infiltrating T 
cells might be overruled if a high number of IL-17+ cells 
are present.
Among patients with HPV-positive tumors, we specifi-
cally found correlations with improved disease-free sur-
vival for high frequencies of both non-Treg T cells and 
Tregs. A high number of Tregs also showed a trend toward 
a correlation with improved disease-specific survival in 
HPV-positive OPSCC. The role of Tregs is controversial 
in OPSCC [16]. We have shown before that a high T cell 
infiltration in cervical cancer is correlated with improved 
prognosis [39], with specifically a low T cell/Tregs ratio 
within the tumor epithelium being correlated with poor 
survival [40, 41]. Indeed, only a high intra-epithelial total 
T cell frequency remained significantly correlated with 
disease-free survival in the multivariate analyses performed 
here. Because we now show that the intra-tumoral Treg fre-
quency was increased and strongly correlated with the total 
T cell frequency in a ratio that favors the infiltration of non-
Treg T cells in HPV-positive OPSCC, the positive role of 
Tregs in oropharyngeal cancer may also rely on their co-
infiltration with effector T cells. The current data suggest 
that a high T cell infiltrate, including Tregs, is correlated 
with improved prognosis in HPV-positive OPSCC.
A minor Th17 cell population was observed, which was 
not significantly different between HPV-positive and HPV-
negative tumors. However, we showed that T cells infil-
trating HPV-positive tumors produced significantly higher 
amounts of IL-17 compared to T cells infiltrating HPV-neg-
ative tumors. This activated state may be an indication that 
Th17 cells are associated with a tumor-targeting immune 
response. In agreement, Partlová et al. [34] also showed 
that cell suspensions prepared from HPV-positive head and 
neck squamous cell carcinoma produced more IL-17 than 
cell suspensions from HPV-negative tumors. These data 
together strongly suggest that Th17 cells are more active 
in HPV-positive tumors. The seemingly opposing small 
population size and large potential of Th17 cells might be 
explained by their stem cell-like phenotype [42] and poten-
tial for plasticity [43]. This corresponds with the correla-
tions described between Th17 cells and improved cancer 
patient survival [27], including our study in squamous cer-
vical cancer [26].
We did not find any direct correlations between the infil-
trating immune cell frequencies investigated and disease-
free or disease-specific survival in HPV-negative tumors. 
Only the T cell/IL-17+ non-T cell ratio was significantly 
correlated with disease-specific survival, again suggesting 
that the beneficial effect of T cells may be lost because of 
the higher numbers of IL-17+ non-T cells present in HPV-
negative OPSCC.
To conclude, HPV-positive OPSCC contain higher num-
bers of tumor-infiltrating T cells, more active Th17 cells 
and lower numbers of IL-17+ non-T cells. Future stud-
ies should evaluate whether this is a general signature of 
a beneficial tumor-targeting immune response. This would 
provide a rationale to study the role and potential of T cell 
administration or IL-17 blockade.
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